Spranger et al. have revealed that melanoma cell-intrinsic β-catenin signaling induces the exclusion of T-cells in the tumor microenvironment and renders resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy [46]. This evidence concerns the gene CTLA4 and melanoma.